Treatment-Related ARs in Safety Population of SIRveNIB, SARAH, and SORAMIC Trials
| SIRT | Sorafenib | P | Risk difference | ||||||||
| Study | SIRveNIB | SARAH | SORAMIC* | Combined | SIRveNIB | SARAH | SORAMIC | Combined | Risk | 95% CI | |
| AE (%) | 41/130 (31.5) | 173/226 (77.0) | 113/159 (71.1) | 327/515 (63.5) | 121/162 (74.7) | 203/216 (94.0) | 139/197 (70.6) | 463/575 (80.5) | 0.01 | −0.17 | −0.22 to −0.12 |
| AE ≥ 3 (%) | 17/130 (13.1) | 92/226 (41.0) | 40/159 (25.2) | 149/515 (28.9) | 61/162 (37.7) | 136/216 (63.0) | 52/197 (26.4) | 249/575 (43.3) | <0.01 | −0.14 | −0.20 to −0.09 |
| SAEs (%) | 6/130 (4.6) | 45/226 (20) | 63/159 (39.6) | 114/515 (22.1) | 15/162 (9.3) | 56/216 (26.0) | 78/197 (39.6) | 149/575 (25.9) | 0.3 | −0.05 | −0.12 to 0.02 |
↵* In SIRT arm, 114/159 patients received sorafenib after SIRT.
SAE = serious AE.